Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The study will determine the benefit of Colchicine versus placebo for cardiac surgery
patients on the post-operative development of atrial fibrillation and post-pericardiotomy
syndrome.
Primary Objective. Colchicine will reduce the composite endpoint of incidence of
post-operative atrial fibrillation and post-pericardiotomy syndrome at 3 months following
cardiac surgery.
Secondary Objectives.
1. Colchicine will reduce the incidence of constrictive physiology on echocardiography at 3
months following cardiac surgery.
2. Reduction in the burden of symptomatic and asymptomatic atrial fibrillation in the 3
months following cardiac surgery with the use of colchicine.